Interaction of MBL2 coding genotype and myeloablative TBI and outcome following transplantation
| . | Major infection . | Acute GVHD . | Grades II-IV acute GVHD . | |||
|---|---|---|---|---|---|---|
| CIF plus or minus SE . | P . | CIF plus or minus SE . | P . | CIF plus or minus SE . | P . | |
| Interaction of mTBI and donor MBL2 mutation | .003 | .750 | .916 | |||
| mTBI−, D MBL2 wt | 32.1 ± 6.3 | 47.1 ± 6.8 | 30.8 ± 6.3 | |||
| mTBI−, D mutation | 40.6 ± 8.9 | 59.4 ± 8.9 | 31.3 ± 8.4 | |||
| mTBI+, D MBL2 wt | 50.8 ± 9.8 | 50.0 ± 9.7 | 35.7 ± 9.3 | |||
| mTBI+, D mutation | 76.2 ± 10.0 | 47.6 ± 11.3 | 28.6 ± 10.2 | |||
| Interaction of mTBI and recipient MBL2 mutation | .013 | .407 | .636 | |||
| mTBI−, R MBL2 wt | 31.1 ± 6.0 | 49.9 ± 6.5 | 31.6 ± 6.1 | |||
| mTBI−, R mutation | 44.4 ± 9.8 | 59.3 ± 9.8 | 29.6 ± 9.0 | |||
| mTBI+, R MBL2 wt | 57.2 ± 9.2 | 43.8 ± 9.0 | 28.1 ± 8.1 | |||
| mTBI+, R mutation | 70.6 ± 11.9 | 58.8 ± 12.6 | 41.2 ± 12.4 | |||
| . | Major infection . | Acute GVHD . | Grades II-IV acute GVHD . | |||
|---|---|---|---|---|---|---|
| CIF plus or minus SE . | P . | CIF plus or minus SE . | P . | CIF plus or minus SE . | P . | |
| Interaction of mTBI and donor MBL2 mutation | .003 | .750 | .916 | |||
| mTBI−, D MBL2 wt | 32.1 ± 6.3 | 47.1 ± 6.8 | 30.8 ± 6.3 | |||
| mTBI−, D mutation | 40.6 ± 8.9 | 59.4 ± 8.9 | 31.3 ± 8.4 | |||
| mTBI+, D MBL2 wt | 50.8 ± 9.8 | 50.0 ± 9.7 | 35.7 ± 9.3 | |||
| mTBI+, D mutation | 76.2 ± 10.0 | 47.6 ± 11.3 | 28.6 ± 10.2 | |||
| Interaction of mTBI and recipient MBL2 mutation | .013 | .407 | .636 | |||
| mTBI−, R MBL2 wt | 31.1 ± 6.0 | 49.9 ± 6.5 | 31.6 ± 6.1 | |||
| mTBI−, R mutation | 44.4 ± 9.8 | 59.3 ± 9.8 | 29.6 ± 9.0 | |||
| mTBI+, R MBL2 wt | 57.2 ± 9.2 | 43.8 ± 9.0 | 28.1 ± 8.1 | |||
| mTBI+, R mutation | 70.6 ± 11.9 | 58.8 ± 12.6 | 41.2 ± 12.4 | |||
CIF indicates cumulative incidence fraction; SE, standard error; mTBI, myeloablative TBI; D, donor; wt, wild type; and R, recipient.